Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Lifecore Biomedical ( (LFCR) ) has shared an update.
On October 29, 2025, Lifecore Biomedical held its annual meeting of stockholders, where three key proposals were addressed. Stockholders elected nine directors, ratified the appointment of KPMG LLP as the independent auditor for the fiscal year ending December 31, 2025, and approved the executive compensation package. These decisions are expected to influence the company’s governance and financial oversight, potentially impacting its strategic direction and stakeholder confidence.
The most recent analyst rating on (LFCR) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Lifecore Biomedical stock, see the LFCR Stock Forecast page.
Spark’s Take on LFCR Stock
According to Spark, TipRanks’ AI Analyst, LFCR is a Neutral.
Lifecore Biomedical’s overall stock score is primarily impacted by its poor financial performance, characterized by declining revenue, high leverage, and negative cash flow. Technical analysis shows mixed signals, with bearish momentum prevailing. The valuation is unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on LFCR stock, click here.
More about Lifecore Biomedical
Lifecore Biomedical, Inc. operates in the biomedical industry, focusing on the development and production of biomaterials and medical devices. The company is known for its expertise in manufacturing hyaluronan-based products, which are used in various medical applications, including ophthalmology, orthopedics, and drug delivery.
Average Trading Volume: 165,528
Technical Sentiment Signal: Hold
Current Market Cap: $266M
See more insights into LFCR stock on TipRanks’ Stock Analysis page.